The phosphatidylinositol-3 kinase or PI3K signaling pathway has been identified as a valid target in a large number of cancers. It is probably one of the most important pathways in cancer metabolism and growth. Mutations in the PI3K pathway are frequent in breast cancer, ovarian and endometrial cancers, causing resistance to human epidermal growth factor receptor 2–targeted agents and, possibly, to hormonal agents as well. Available agents that affect the PI3K pathway include monoclonal…

About 5% of all breast cancers are attributed to an inherited mutation in one of two cancer susceptibility genes, BRCA1 and BRCA2. Researchers how now developed a new multiple gene expression profile test was able to predict the presence of either BRCA1 or BRCA2 mutations in otherwise healthy women carrying the mutations, according to data published in Cancer Prevention Research, a…

Treatment with a recombinant poxviral vaccine showed a positive response in both metastatic breast cancer and ovarian cancer, according to a trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR)the world’s oldest and largest professional organization dedicated to advancing cancer research.



“With this vaccine, we can clearly generate immune responses…

Women planning on taking hormone therapy for the treatment of menopausal symptoms should be aware of a possible increased risk for ovarian cancer, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held in Philadelphia from November 7-10, 2010.



“This study is consistent with previous recommendations that say if women are going to take hormones they should only take them in the short term,” said…